Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay

Acta Pharmacologica Sinica

Volumn 29, Issue 4, 2008, Pages 517-527

  Meng, Tao ^a   Su, Hao Ran ^a,b   Binkert, Christoph ^c   Fischli, Walter ^c   Zhou, Ling ^a,b   Shen, Jing Kang ^a   Wang, Ming Wei ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b National Center for Drug Screening   (China)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Modulators; Neuromedin U; Receptors; Structure activity relationship

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROMEDIN U RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CHO CELL; CONTROLLED STUDY; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL ASSAY; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, NEUROTRANSMITTER; REPRODUCIBILITY OF RESULTS; SCINTILLATION COUNTING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41549108147     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00769.x     Document Type: Article

References (35)

1. Minamino N, Sudoh T, Kangawa K, Matsuo H. Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides 1985 6 Suppl 3: 245 8.
2. Minamino N, Kangawa K, Matsuo H. Neuromedin U-8 and neuromedin U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal-cord. Biochem Biophys Res Commun 1985 130: 1078 85.
3. Brighton PJ, Szekeres PG, Willars GB. Neuromedin U and its receptors: structure, function and physiological roles. Pharmacol Rev 2004 56: 231 48.
4. Sumi S, Inoue K, Kogire M, Doi R, Takaori K, Tobe T, et al. Effect of synthetic neuromedin U-8 and U-25, novel peptides identified in porcine spinal-cord, on splanchnic circulation in dogs. Life Sci 1987 41: 1585 90.
5. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Liu Q, et al. Identification of receptors for neuromedin U and its role in feeding. Nature 2000 406: 70 4.
6. Nakazato M, Hanada R, Murakami N, Date Y, Mondal MS, Matsukura S, et al. Central effects of neuromedin U in the regulation of energy homeostasis. Biochem Biophys Res Commun 2000 277: 191 4.
7. Ivanov TR, Lawrence CB, Stanley PJ, Luckman SM. Evaluation of neuromedin U actions in energy homeostasis and pituitary function. Endocrinology 2002 143: 3813 21.
8. Hanada R, Nakazato M, Murakami N, Sakihara S, Yoshimatsu H, Sakata T, et al. A role for neuromedin U in stress response. Biochem Biophys Res Commun 2001 289: 225 8.
9. Yu XH, Cao CQ, Mennicken F, Puma C, Dray A, Perkins M, et al. Pro-nociceptive effects of neuromedin U in rat. Neuroscience 2003 120: 467 74.
10. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Wong DT, et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 2001 20: 6196 204.
11. Shetzline SE, Rallapalli R, Dowd KJ, Zou SM, Nakata Y, Gewirtz AM, et al. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 2004 104: 1833 40.
12. Wu Y, McRoberts K, Berr SS, Frierson HF Jr., Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2006 26: 765 73.
13. Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kojima M, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 2005 202: 217 24.
14. Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Habata Y, Hinuma S, et al. Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3. J Biol Chem 2000 275: 21068 74.
15. Hosoya M, Moriya T, Kawamata Y, Ohkubo S, Fujii R, Matsui H, et al. Identification and functional characterization of a novel subtype of neuromedin U receptor. J Biol Chem 2000 275: 29528 32.
16. Kojima M, Haruno R, Nakazato M, Date Y, Murakami N, Hanada R, et al. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem Biophys Res Commun 2000 276: 435 8.
17. Shan L, Qiao X, Crona JH, Behan J, Wang S, Laz T, et al. Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J Biol Chem 2000 275: 39482 6.
18. Szekeres PG, Muir AI, Spinage LD, Miller JE, Butler SI, Smith A, et al. Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. J Biol Chem 2000 275: 20247 50.
19. Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Adham N et al. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J Biol Chem 2000 275: 32452 9.
20. Qian J, Voorbach MJ, Huth JR, Coen ML, Zhang HC, Ng SC, et al. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal Biochem 2004 328: 131 8.
21. 50) of an enzymatic reaction. Biochem Pharmacol 1973 22: 3099 108.
22. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 4: 67 73.
23. Hashimoto T, Masui H, Uchida Y, Sakura N, Okimura K. Agonistic and antagonistic activities of neuromedin U-8 analogs substituted with glycine or D-amino acid on contractile activity of chicken crop smooth muscle preparations. Chem Pharm Bull (Tokyo) 1991 39: 2319 22.
24. Sakura N, Ohta S, Uchida Y, Kurosawa K, Okimura K, Hashimoto T. Structure-activity relationships of rat neuromedin U for smooth muscle contraction. Chem Pharm Bull (Tokyo) 1991 39: 2016 20.
25. Sakura N, Kurosawa K, Hashimoto T. Structure-activity relationships of neuromedin U. I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle. Chem Pharm Bull (Tokyo) 1995 43: 1148 53.
26. Hashimoto T, Kurosawa K, Sakura N. Structure-activity relationships of neuromedin U. II. Highly potent analogs substituted or modified at the N-terminus of neuromedin U-8. Chem Pharm Bull (Tokyo) 1995 43: 1154 7.
27. Kurosawa K, Sakura N, Hashimoto T. Structure-activity relationships of neuromedin U. III. Contribution of two phenylalanine residues in dog neuromedin U-8 to the contractile activity. Chem Pharm Bull (Tokyo) 1995 44: 1180 4.
28. Sakura N, Kurosawa K, Hashimoto T. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity. Chem Pharm Bull (Tokyo) 2000 48: 1166 70.
29. Abiko T, Takamura Y. Synthesis of two neuromedin U (NMU) analogues and their comparative effect of reducing food intake in rats. Prep Biochem Biotechnol 2002 32: 79 86.
30. Wu B, Gao J, Wang MW. Development of a complex scintillation proximity assay for high-throughput screening of PPARy modulators. Acta Pharmacol Sin 2005 26: 339 44.
31. Hui X, Gao J, Xie X, Suto N, Ogiku T, Wang MW. A robust homogeneous binding assay for α4β2 nicotinic acetylcholine receptor. Acta Pharmacol Sin 2005 26: 1175 80.
32. Go bel J, Saussy DL, Goetz AS. Development of scintillation-proximity assays for alpha adrenoceptors. J Pharmacol Toxicol Methods 1999 42: 237 44.
33. Gleich A, Schmidtchen FP, Mikulcik P, Müller G. Enantiodifferentiation of carboxylates by chiral building blocks for abiotic anion receptors. J Chem Soc Chem Commun 1990 55 7.
34. Foye WO, Lemke TL, Williams DA (eds) Foye's principles of medicinal chemistry; v 4. Pennsylvania: Williams and Wilkins 1995. Chapters 11-14, 17 18.
35. Kajino M, Hinuma S, Tarui N, Yamashita T, Nakayama Y, inventors; Receptor regulator. EP 1 559 428 A1, 03.08.2005.